

EQA round: IHC1/23 - Immunohistochemistry - Detection of HER-2/neu

Deadline: 24.2.2023

Setup: groups - manufacturer of kit

AV = assigned value

N_{tot} = total number of the resultsN_{eva} = number of the results assessed

CVE = consensus of the experts

N_{rel} = relative number of the resultsN_{suc} = number of successful results

>>> ... expected result

S_{rel} = relative success

> ... acceptable result

± ... result not assessed

Test Sample Group	Frequency of the results					Success		
	AV	N _{tot}	N _{rel} [%]	Result	N _{eva}	N _{suc}	S _{rel} [%]	
(601) A1 expression HER-2/neu		49			49	45	92	
Slide		49			49	45	92	
(802) Dako HercepTest	CVE >>>	6	12	Weak positive (2+)				
	>	1	2	Strong positive (3+)				
(803) Dako c-erbB-2 Onkoprotein	CVE >>>	12	24	Weak positive (2+)				
	>	1	2	Strong positive (3+)				
(804) Ventana PATHWAY anti-HER-2/neu	CVE >>>	3	6,1	Negative (1+)				
	>>>	22	45	Weak positive (2+)				
(999) another manufacturer	CVE >>>	1	2	Negative (1+)				
	>>>	3	6,1	Weak positive (2+)				
(602) A2 expression HER-2/neu		49			49	43	88	
Slide		49			49	43	88	
(802) Dako HercepTest	CVE >>>	3	6,1	Negative (0)				
	>>>	3	6,1	Negative (1+)				
		1	2	Weak positive (2+)				
(803) Dako c-erbB-2 Onkoprotein	CVE >>>	1	2	Negative (0)				
	>>>	9	18	Negative (1+)				
		3	6,1	Weak positive (2+)				
(804) Ventana PATHWAY anti-HER-2/neu	CVE >>>	5	10	Negative (0)				
	>>>	18	37	Negative (1+)				
		2	4,1	Weak positive (2+)				
(999) another manufacturer	CVE >>>	4	8,2	Negative (1+)				
(603) A3 expression HER-2/neu		39			0			
Slide		39			0			
(802) Dako HercepTest	±	3	7,7	Negative (1+)				
	±	2	5,1	Weak positive (2+)				
	±	1	2,6	Strong positive (3+)				
(803) Dako c-erbB-2 Onkoprotein	±	1	2,6	Negative (0)				
	±	9	23	Negative (1+)				
	±	2	5,1	Weak positive (2+)				
(804) Ventana PATHWAY anti-HER-2/neu	±	2	5,1	Negative (0)				
	±	14	36	Negative (1+)				
	±	3	7,7	Weak positive (2+)				
(999) another manufacturer	±	1	2,6	Negative (1+)				
	±	1	2,6	Weak positive (2+)				
(606) B1 expression HER-2/neu		49			49	49	100	
Slide		49			49	49	100	
(802) Dako HercepTest	CVE >>>	7	14	Strong positive (3+)				
(803) Dako c-erbB-2 Onkoprotein	>	1	2	Weak positive (2+)				
	CVE >>>	12	24	Strong positive (3+)				
(804) Ventana PATHWAY anti-HER-2/neu	>	4	8,2	Weak positive (2+)				
	CVE >>>	21	43	Strong positive (3+)				
(999) another manufacturer	CVE >>>	4	8,2	Strong positive (3+)				
(607) B2 expression HER-2/neu		49			49	49	100	
Slide		49			49	49	100	
(802) Dako HercepTest	CVE >>>	7	14	Negative (0)				
(803) Dako c-erbB-2 Onkoprotein	CVE >>>	12	24	Negative (0)				
	>	1	2	Negative (1+)				
(804) Ventana PATHWAY anti-HER-2/neu	CVE >>>	25	51	Negative (0)				
(999) another manufacturer	CVE >>>	4	8,2	Negative (0)				
(608) B3 expression HER-2/neu		43			43	43	100	
Slide		43			43	43	100	
(802) Dako HercepTest	CVE >>>	6	14	Negative (0)				
(803) Dako c-erbB-2 Onkoprotein	CVE >>>	9	21	Negative (0)				
(804) Ventana PATHWAY anti-HER-2/neu	CVE >>>	24	56	Negative (0)				
(999) another manufacturer	CVE >>>	4	9,3	Negative (0)				
(611) C1 expression HER-2/neu		49			49	49	100	
Slide		49			49	49	100	
(802) Dako HercepTest	CVE >>>	7	14	Strong positive (3+)				
(803) Dako c-erbB-2 Onkoprotein	CVE >>>	13	27	Strong positive (3+)				
(804) Ventana PATHWAY anti-HER-2/neu	CVE >>>	25	51	Strong positive (3+)				
(999) another manufacturer	CVE >>>	4	8,2	Strong positive (3+)				

Setup: groups - manufacturer of kit

Test Sample Group	Frequency of the results				Success		
	AV	N _{tot}	N _{rel} [%]	Result	N _{eva}	N _{suc}	S _{rel} [%]
(612) C2 expression HER-2/neu		49			49	49	100
Slide		49			49	49	100
(802) Dako HercepTest	CVE >>>	7	14	Strong positive (3+)			
(803) Dako c-erbB-2 Onkoprotein	>	1	2	Weak positive (2+)			
	CVE >>>	12	24	Strong positive (3+)			
(804) Ventana PATHWAY anti-HER-2/neu	CVE >>>	25	51	Strong positive (3+)			
(999) another manufacturer	CVE >>>	4	8,2	Strong positive (3+)			
(613) C3 expression HER-2/neu		49			49	49	100
Slide		49			49	49	100
(802) Dako HercepTest	CVE >>>	7	14	Strong positive (3+)			
(803) Dako c-erbB-2 Onkoprotein	CVE >>>	13	27	Strong positive (3+)			
(804) Ventana PATHWAY anti-HER-2/neu	CVE >>>	25	51	Strong positive (3+)			
(999) another manufacturer	CVE >>>	4	8,2	Strong positive (3+)			
(616) D1 expression HER-2/neu		49			49	48	98
Slide		49			49	48	98
(802) Dako HercepTest	CVE >>>	6	12	Weak positive (2+)			
	>	1	2	Strong positive (3+)			
(803) Dako c-erbB-2 Onkoprotein	CVE >>>	9	18	Weak positive (2+)			
	>	4	8,2	Strong positive (3+)			
(804) Ventana PATHWAY anti-HER-2/neu		1	2	Negative (1+)			
	CVE >>>	24	49	Weak positive (2+)			
(999) another manufacturer	CVE >>>	4	8,2	Weak positive (2+)			
(617) D2 expression HER-2/neu		49			49	48	98
Slide		49			49	48	98
(802) Dako HercepTest	CVE >>>	6	12	Weak positive (2+)			
	>	1	2	Strong positive (3+)			
(803) Dako c-erbB-2 Onkoprotein	CVE >>>	9	18	Weak positive (2+)			
	>	4	8,2	Strong positive (3+)			
(804) Ventana PATHWAY anti-HER-2/neu		1	2	Negative (1+)			
	CVE >>>	24	49	Weak positive (2+)			
(999) another manufacturer	CVE >>>	4	8,2	Weak positive (2+)			
(618) D3 expression HER-2/neu		49			49	47	96
Slide		49			49	47	96
(802) Dako HercepTest	CVE >>>	6	12	Weak positive (2+)			
	>	1	2	Strong positive (3+)			
(803) Dako c-erbB-2 Onkoprotein	CVE >>>	9	18	Weak positive (2+)			
	>	4	8,2	Strong positive (3+)			
(804) Ventana PATHWAY anti-HER-2/neu		1	2	Negative (1+)			
	CVE >>>	24	49	Weak positive (2+)			
(999) another manufacturer		1	2	Negative (1+)			
	CVE >>>	3	6,1	Weak positive (2+)			
(621) E1 expression HER-2/neu		49			49	33	67
Slide		49			49	33	67
(802) Dako HercepTest	CVE >>>	5	10	Negative (1+)			
		2	4,1	Weak positive (2+)			
(803) Dako c-erbB-2 Onkoprotein	CVE >>>	8	16	Negative (1+)			
		5	10	Weak positive (2+)			
(804) Ventana PATHWAY anti-HER-2/neu	>	2	4,1	Negative (0)			
	CVE >>>	16	33	Negative (1+)			
		7	14	Weak positive (2+)			
(999) another manufacturer	CVE >>>	2	4,1	Negative (1+)			
		2	4,1	Weak positive (2+)			
(622) E2 expression HER-2/neu		49			49	46	94
Slide		49			49	46	94
(802) Dako HercepTest	CVE >>>	7	14	Negative (1+)			
(803) Dako c-erbB-2 Onkoprotein	>	4	8,2	Negative (0)			
	CVE >>>	9	18	Negative (1+)			
(804) Ventana PATHWAY anti-HER-2/neu	>	8	16	Negative (0)			
	CVE >>>	15	31	Negative (1+)			
		2	4,1	Weak positive (2+)			
(999) another manufacturer	>	1	2	Negative (0)			
	CVE >>>	2	4,1	Negative (1+)			
		1	2	Weak positive (2+)			
(623) E3 expression HER-2/neu		48			48	44	92
Slide		48			48	44	92
(802) Dako HercepTest	CVE >>>	3	6,3	Negative (0)			
	CVE >>>	3	6,3	Negative (1+)			
		1	2,1	Weak positive (2+)			
(803) Dako c-erbB-2 Onkoprotein	CVE >>>	4	8,3	Negative (0)			

EQA round: IHC1/23 - Immunohistochemistry - Detection of HER-2/neu

Deadline: 24.2.2023

Setup: groups - manufacturer of kit

Test Sample Group	Frequency of the results				Success		
	AV	N _{tot}	N _{rel} [%]	Result	N _{eva}	N _{suc}	S _{rel} [%]
(804) Ventana PATHWAY anti-HER-2/neu	CVE >>>	9	19	Negative (1+)			
	CVE >>>	9	19	Negative (0)			
	CVE >>>	13	27	Negative (1+)			
(999) another manufacturer		2	4,2	Weak positive (2+)			
	CVE >>>	2	4,2	Negative (0)			
	CVE >>>	1	2,1	Negative (1+)			
		1	2,1	Weak positive (2+)			